Associate Professor Vincent Murray
- Cancer Institute, Melbourne 1982-1990
- Princeton University 1980-1982
I have been an active researcher in the field of molecular biology for 30 years.
The overall aim of my lab is to develop more effective cancer chemotherapeutic agents based on cisplatin and bleomycin. Cisplatin and bleomycin are widely used in the clinic: cisplatin is used to treat testicular and ovarian cancer while bleomycin is utilised to treat germ cell tumours, certain types of lymphoma and squamous cell carcinomas. Both compounds are thought to act by damaging DNA inside tumour cells. Cisplatin preferentially targets G-rich DNA sequences while bleomycin targets GT and GC DNA sequences.
My lab has made significant research contributions, demonstrated by publication of over 65 papers in high profile international refereed journals. I have published 3 papers in the Journal of Biological Chemistry (impact factor 5.8) and 8 in Nucleic Acids Research (impact factor 6.3). One of my Nucleic Acids Research articles has been cited over 400 times; and 13 of my papers have been cited more than 30 times.
I have given seminars at 19 international and local conferences and seminar series and have helped to organise 4 conferences, and was invited to speak at the 6th Annual Congress of International Drug Discovery Science and Technology in Beijing in 2008.
Active Research Projects
Nguyen, T.V. & Murray, V. (2013)
The electrophoretic mobility of DNA fragments differing by a single 3'-terminal nucleotide in an automated capillary DNA sequencer.
Biomedical Chromatography. (In Press) DOI: 10.1002/bmc.2804.
Nguyen, H.T., Galea, A.M. & Murray, V. (2013)
The interaction of cisplatin with a human telomeric DNA sequence containing seventeen tandem repeats.
Bioorganic and Medicinal Chemistry Letters. 23: 1041-1045.
Nguyen, T.V., Chen, J.K. & Murray, V. (2013)
Bleomycin DNA damage: Anomalous mobility of 3ˇ-phosphoglycolate termini in an automated capillary DNA sequencer.
Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences. Jan 15: 113-122. doi: 10.1016/j.jchromb.2012.11.029.
Murray, V., Campbell, H.M. & Gero, A.M. (2012)
Plasmodium falciparum: The potential of the cancer chemotherapeutic agent cisplatin and its analogues as anti-malarials.
Experimental Parasitology. 132(4): 440-443.
Lung, M.S., Zhang, N. & Murray, V. (2012)
Site-directed mutagenesis of human papillomavirus 18 promoter elements and issue-specific expression in cervical carcinoma cells.
Virus Genes. 44(3): 395-402.
Murray, V., Nguyen, T.V.T. & Chen, J.K. (2012)
The use of automated sequencing techniques to investigate the sequence selectivity of DNA-damaging agents.
Chemical Biology and Drug Design. 80(1): 1-8.
Murray, V. & Kandasamy, N. (2012)
The sequence specificity of the anti-tumour drug, cisplatin, in telomeric DNA sequences compared with consecutive guanine DNA sequences.
Anti-Cancer Agents in Medicinal Chemistry. 12(3): 177-181.
Nguyen, H.T. & Murray, V. (2012)
The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells.
Journal of Biological Inorganic Chemistry. 17(8): 1209-1215.
Nguyen, T.V. & Murray, V. (2012)
Human telomeric DNA sequences are a major target for the anti-tumour drug, bleomycin.
Journal of Biological Inorganic Chemistry. 17(1): 1-9.
Paul, M. & Murray, V. (2012)
Use of an automated capillary DNA sequencer to investigate the interaction of Cisplatin with Telomeric DNA sequences.
Biomedical Chromatography. 26(3): 350-354.
Murray, V. & Galea, A.M. (2012)
Gene expression profiling of the cancer chemotherapeutic agent, Cisplatin, compared with its ineffective isomer, Transplatin.
Journal of Computer Science and Systems Biology. 5:37. doi.org/10.4172/0974-7230.S1.02
Murray, V., Campbell, H.M. & Gero, A.M. (2011)
Plasmodium falciparum: DNA sequence specificity of cisplatin and cisplatin analogues.
Experimental Parasitology. 128: 396-400.
Paul, M. & Murray, V. (2011)
The sequence selectivity of DNA-targeted 9-aminoacridine cisplatin analogues in a telomere-containing DNA sequence.
Journal of Biological Inorganic Chemistry. 16: 735-743.
Paul, M. & Murray, V. (2011)
Use of an automated capillary DNA sequencer to investigate the interaction of cisplatin with telomeric DNA sequences.
Biomedical Chromatography. 26: 350-354.
Galea, A.M. & Murray, V. (2010)
The influence of chromatin structure on DNA damage induced by nitrogen mustards and cisplatin analogues.
Chemical Biology and Drug Design. 75: 578-589.
Carland, M., Grannas, M.J., Cairns, M.J., Roknic, V.J., Denny, W.A., McFadyen, W.D. & Murray, V. (2010)
Substituted 9-amino-acridine-4-carboxamides tethered to platinum(II)diamine complexes: Chemistry, cytotoxicity and DNA sequence selectivity.
Journal of Inorganic Biochemistry. 104(8): 815-819.
Holmes, R.J., Abrahams, B.F., Murray, V., Denny, W.A. & McFadyen, W.D. (2010)
A 2D hydrogen-bonded network constructed from large organic dications.
Journal of Molecular Structure. 975(1-3): 186-189.
Murray, V. (2010)
Nucleosomes and Cisplatin.
Chemistry and Biology. 17: 1271-1272.
Cairns, M.J., Carland, M., McFadyen, W.D., Denny, W.A. & Murray, V. (2009)
The DNA sequence selectivity of maltolato-containing cisplatin analogues in purified plasmid DNA and in intact human cells.
Journal of Inorganic Biochemistry. 103: 1151-1155.
Galea, A.M. & Murray, V. (2008)
The anti-tumour agent, Cisplatin, and its clinically ineffective isomer, Transplatin, produce unique gene expression profiles in human cells.
Cancer Informatics. 6: 315–355.